Navigation Links
Tapestry Announces Strategy to Focus on TPI 287 Clinical Program
Date:10/26/2007

al approvals, patient recruitment, formulation and manufacturing difficulties, delays in finalizing and receiving approval of protocols, negotiations with regulatory agencies, or other factors; that human clinical trials may show that TPI 287 is unsafe and/or ineffective in treating cancer in humans. General implementation risks associated with development of TPI 287 include those that we are blocked or limited in the development of TPI 287 because of the intellectual property rights of third parties; that we are limited in our ability to obtain, maintain and enforce our own intellectual property; that development of TPI 287 is delayed or terminated because the costs of further development exceed its value; and that the Company's resources will be insufficient to continue development, whether as a result of the Company's inability to raise additional cash or otherwise. Additional risks, uncertainties and other factors are identified under the captions "Risk Factors" and "Special Note Regarding Forward-Looking Statements" in the Company's reports filed from time to time with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q for the periods ended March 28, 2007, and June 27, 2007. The Company cautions investors not to place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update publicly or revise any forward-looking statements, whether as a result of new or additional information, future events or otherwise.

Contact: Tapestry Pharmaceuticals, Inc.

Gordon Link

Senior Vice President, Chief Financial Officer

303-516-8500

glink@tapestrypharma.com

Investor: Laura Perry

Stern Investor Relations, Inc.

212-362-1200

laura@sternir.com

Media: Lloyd Benson/Dana Conti


'/>"/>

SOURCE Tapestry Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tapestry Pharmaceuticals to Present Data on TPI 287 at the 2007 AACR Annual Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Calif. , May 4, 2015 Unchained ... coming out to this year,s PEGS conference and launches ... stability system for biologics. PEGS: The Essential Protein Engineering ... May 4-8, 2015. The UNit lets drug ... any other tool out there. Its 7 applications, 144 ...
(Date:5/4/2015)... newest member of the cuvette manufacturing world, opened their doors to the public in ... head by offering scientists amazing support for their spectroscopy needs.  ... ... ... In mid-2014 ...
(Date:5/4/2015)... CONCORD, N.H. , May 4, 2015 /PRNewswire/ ... creating analytic and technology solutions to improve healthcare ... Bedford Nursing & Rehabilitation Center (BNRC) use ... monitoring platform to improve the quality and lower ... analytics platform integrates clinical, outcomes, claims and utilization ...
Breaking Medicine Technology:Unchained Labs Lets the UNit Loose 2New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 2New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 3Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 2Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 3
... , HOUSTON, Oct. 5 PAC, a leading global ... process applications, announces the introduction of the ANTEK MultiTek(TM) ... sulfur , nitrogen, and halides. Industries include ... Pharmaceutical, Environmental, and many more. , "MultiTek(TM) is ...
... , SAN DIEGO, Oct. 2 Pharmatek Laboratories, Inc., ... pharmaceutical industry, announced that it is the first CRO ... enhancing the company,s preclinical and early phase clinical GMP ... to move our customers, drug candidates into the clinic ...
Cached Medicine Technology:New ANTEK MultiTek(TM) by PAC Provides Fast, All-in-One Testing for Sulfur, Nitrogen, Halides 2Pharmatek Laboratories Announces Acquisition of the First Xcelodose(R) 600S System on the West Coast 2
(Date:5/4/2015)... Charlottesville, VA (PRWEB) May 04, 2015 Ticket ... tickets at the John Paul Jones Arena in Charlottesville, ... in the history of the music business and this beloved ... down. Paul McCartney, the former member of two legendary groups: ... decades in the music business since 2013 on the “Out ...
(Date:5/4/2015)... SC (PRWEB) May 04, 2015 Ticket Down ... at the Colonial Life Arena in Columbia, South Carolina. ... the continuation of his “Out There” tour which originally kicked ... long tour is North America and the legendary performer recently ... at the Wells Fargo Arena on June 21st, in Charlottesville, ...
(Date:5/4/2015)... May 04, 2015 New findings released ... Tumor Association (ABTA) show that people diagnosed with a ... treatment options, including clinical trials, at the time of ... make difficult decisions about their course of treatment. The ... the first nationwide brain tumor volunteer network, the ABTA ...
(Date:5/4/2015)... Greensboro, NC (PRWEB) May 04, 2015 ... excited to offer this unique program to other leadership ... create valuable ties between CCL and successful practitioners, expanding ... organizations around the globe,” said John R. Ryan, CCL ... consultancy joins the CCL Partner Network , it ...
(Date:5/4/2015)... American Fork, UT (PRWEB) May 04, 2015 ... the surgery (up to $3,000) of one patient receiving care ... corner of Utah. The procedure must be performed by ... customer (willing to pay in full up front and forego ... the U.S. becomes more economically burdensome every year, and it ...
Breaking Medicine News(10 mins):Health News:Paul McCartney Tickets at John Paul Jones Arena in Charlottesville, VA: Ticket Down Slashes Paul McCartney Ticket Prices in Charlottesville at the John Paul Jones Arena 2Health News:Paul McCartney Tickets at Colonial Life Arena in Columbia, SC: Ticket Down Slashes Paul McCartney Ticket Prices in Columbia, South Carolina at Colonial Life Arena 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3Health News:The Center for Creative Leadership Is Partnering with Lead Star to Create the CCL Partner Network 2Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 2Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 3
... ... the 62nd Annual Conference of the Society for Human Resources Management (SHRM). During the ... integration to Human Resource and Payroll professionals at Booth #531 , ... Monterey Park, Calif. (Vocus) June 25, ...
... wine, grapes, blueberries, peanuts and other plants stops ... vision researchers at Washington University School of Medicine in ... vision in blinding eye diseases such as diabetic retinopathy ... in Americans over 50. The formation of new ...
... ... first patent pending method that allows for significant risk reduction for index ... the losses significantly limited or capped while reinvesting index gains accrued to ... Effect." Between 95-100% of the principal value is invested and backed by ...
... ... Values While Creating an Engaged Workforce, , ... Charlotte, NC (Vocus) June 24, 2010 -- ... “Managing the Paradox of Employee Alignment and Engagement.” The free hour-long webinar ...
... HealthDay Reporter , THURSDAY, June 24 (HealthDay News) ... the risk of invasive breast cancer by around 30 ... is considering bisphosphonate use for bone, this might be ... clinical oncologist at the Los Angeles Biomedical Research Institute ...
... trial of a novel radioactive compound readily and safely ... volunteers on brain scans and opens the doors to ... their own radioactive compounds. The results, reported by a ... Nuclear Medicine, could lead to better ways to ...
Cached Medicine News:Health News:NOVAtime participates in the Society for Human Resources Management, (SHRM) 62nd Annual Conference in San Diego, California between June 27 and June 29, 2010 2Health News:NOVAtime participates in the Society for Human Resources Management, (SHRM) 62nd Annual Conference in San Diego, California between June 27 and June 29, 2010 3Health News:Ingredient in red wine may prevent some blinding diseases 2Health News:Ingredient in red wine may prevent some blinding diseases 3Health News:Principal Protected Index Investing Provides Innovative Method to Significantly Reduce Stock Market Loss and Risk 2Health News:Principal Protected Index Investing Provides Innovative Method to Significantly Reduce Stock Market Loss and Risk 3Health News:Morehead Presents Webinar on “Managing the Paradox of Employee Alignment and Engagement”, 2Health News:Bone-Building Pills Appear to Lower Invasive Breast Cancer Risk 2Health News:Bone-Building Pills Appear to Lower Invasive Breast Cancer Risk 3Health News:Novel radiotracer shines new light on the brains of Alzheimer's disease patients 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: